Get the Stockscreener App
0.628
7.17%
0.042
After Hours:
.63
0.002
+0.32%
Rein Therapeutics Inc stock is traded at $0.628, with a volume of 1.37M.
It is up +7.17% in the last 24 hours and down -11.24% over the past month.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
See More
Previous Close:
$0.586
Open:
$0.6
24h Volume:
1.37M
Relative Volume:
2.74
Market Cap:
$54.18M
Revenue:
Net Income/Loss:
$-50.21M
P/E Ratio:
-0.3296
EPS:
-1.9053
Net Cash Flow:
$-16.61M
1W Performance:
-18.37%
1M Performance:
-11.24%
6M Performance:
-64.72%
1Y Performance:
-51.69%
1-Day Range:
$0.551
$0.666
1-Week Range:
$0.5401
$0.81
52-Week Range:
$0.5401
$2.18
Rein Therapeutics Inc Stock (RNTX) Company Profile
Name
Rein Therapeutics Inc
Sector
Industry
Phone
(737) 802-1989
Address
12407 N. MOPAC EXPY., AUSTIN
Compare RNTX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNTX
Rein Therapeutics Inc
|
0.628 | 54.18M | 0 | -50.21M | -16.61M | -1.9053 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-22-25 | Initiated | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-24-17 | Initiated | BofA/Merrill | Buy |
| Jul-24-17 | Initiated | Jefferies | Buy |
| Jul-24-17 | Initiated | William Blair | Outperform |
Rein Therapeutics Inc Stock (RNTX) Latest News
Rein Therapeutics Inc (RNTX-Q) Stock Price and News - The Globe and Mail
Rein Therapeutics (RNTX) Ticks Up 1.37% to $0.80 as Traders Eye ResistanceFibonacci Retracement - dars.gov.et
Rein Therapeutics at cantor global healthcare: ipf push gains traction By Investing.com - Investing.com South Africa
Rein Therapeutics at cantor global healthcare: ipf push gains traction By Investing.com - Investing.com Canada
Rein Therapeutics at cantor global healthcare: ipf push gains traction - Investing.com
Rein Therapeutics at cantor global healthcare: ipf push gains traction - Investing.com India
RNTX: LTI-03 advances in Phase 2 IPF trials after promising safety and biomarker results - TradingView
We're Hopeful That Rein Therapeutics (NASDAQ:RNTX) Will Use Its Cash Wisely - simplywall.st
Rein Therapeutics Highlights LTI-03 Progress in IPF - TipRanks
Rein Therapeutics publishes LTI-03 presentation; Phase 1b biomarker signals and Phase 2 RENEW now enrolling - TradingView
Inhaled IPF drug from Rein Therapeutics (NASDAQ: RNTX) shows early safety data - Stock Titan
A study of an inhaled treatment for lung scarring will be presented Sept. 8 in Barcelona. - Stock Titan
Stay updated with the stocks that are on the move in today's after-hours session. - ChartMill
Rein Therapeutics to Present at Upcoming September Investor Conferences - Yahoo Finance
Here's Why You Should Add RNTX Stock to Your Portfolio Now - The Globe and Mail
Here's Why You Should Add RNTX Stock to Your Portfolio Now - Eastern Progress
Rein Therapeutics Receives Nasdaq Delisting Notice Over Bid Price - The Globe and Mail
Rein Therapeutics Receives Nasdaq Delisting Notice Over Bid Price - TipRanks
Rein Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Rein Therapeutics Inc (NASDAQ: RNTX) Stock Price, News & Analysis - kalkine.ca
Rein (RNTX) Quarter in Focus: The Available Earnings Metric Delivers a Beat on the Day; Post-Report: Shares Move 0.88% Higher in the Current UpdateGuidance Accuracy Score - vinanet.vn
Rein Therapeutics receives FDA fast track for IPF drug LTI-03 - Investing.com Nigeria
Rein Therapeutics receives FDA fast track for IPF drug LTI-03 - Investing.com Australia
Rein Therapeutics receives FDA fast track for IPF drug LTI-03 - Investing.com Canada
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis - The Manila Times
Rein Therapeutics Receives FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis - Quiver Quantitative
Rein Therapeutics Receives U.S. FDA Fast Track Designation For Lti-03 In Idiopathic Pulmonary Fibrosis - TradingView
FDA grants Fast Track designation to inhaled treatment for lung disease with 3-to-5-year median survival - Stock Titan
Equities Analysts Set Expectations for RNTX FY2026 Earnings - MarketBeat
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis - Yahoo Finance
Rein Therapeutics Inc (NASDAQ: RNTX) Stock Price, News & Analysis - Kalkine
What is HC Wainwright's Estimate for RNTX FY2030 Earnings? - MarketBeat
RNTX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus
Rein Therapeutics (NASDAQ:RNTX) Given "Buy" Rating at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Buy on Rein Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Buy on Rein Therapeutics stock By Investing.com - Investing.com UK
RNTX Q1 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates as Stock Climbs 2.35%Tech Earnings Analysis - vinanet.vn
RNTX Q1 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates as Stock Climbs 2.35%Revenue Report - dars.gov.et
Rein Therapeutics (NASDAQ:RNTX) Announces Earnings Results - MarketBeat
Rein Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Rein Therapeutics (RNTX) Holds at $0.79 as Range-Bound Trading PersistsVWAP Bounce - vinanet.vn
Rein Therapeutics raises $44.3M to fund lung-disease drug trial - Dealroom
Rein Therapeutics Raises $44.3 Million in Public Offering - Minichart
Rein Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Rein Therapeutics Surpasses 25% Enrollment in Phase 2 RENEW Trial of LTI-03 for IPF, Completes $57.5 Million Public Offering - Quiver Quantitative
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
Press Release: Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - Moomoo
Rein Therapeutics 2Q 2026: Revenue $0 Net loss $6.4M, EPS $(0.10) — 10-Q Summary - TradingView
RNTX: Q2 net loss narrowed, liquidity strengthened, and Phase 2 LTI-03 trial remains on track - TradingView
Rein Therapeutics Inc Stock (RNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rein Therapeutics Inc Stock (RNTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| VON RICKENBACH JOSEF H | Director |
May 27 '26 |
Buy |
1.07 |
4,500 |
4,819 |
62,514 |
| VON RICKENBACH JOSEF H | Director |
May 22 '26 |
Buy |
1.05 |
15,950 |
16,708 |
34,824 |
| VON RICKENBACH JOSEF H | Director |
May 21 '26 |
Buy |
1.04 |
3,420 |
3,564 |
18,874 |
| WINDSOR JAMES BRIAN | See Remarks |
Apr 30 '26 |
Buy |
1.00 |
25,000 |
25,000 |
27,046 |
| Voss Capital, LP | 10% Owner |
Nov 14 '25 |
Buy |
1.22 |
104,183 |
127,593 |
926,441 |
| Voss Capital, LP | 10% Owner |
Oct 28 '25 |
Buy |
1.39 |
178,392 |
247,965 |
500,000 |
| Voss Capital, LP | 10% Owner |
Oct 27 '25 |
Buy |
1.37 |
97,482 |
133,544 |
822,258 |
| Voss Capital, LP | 10% Owner |
Oct 24 '25 |
Buy |
1.39 |
30,176 |
41,957 |
729,616 |
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):